Veracyte, Inc. (VCYT)
POSITIVEFundamental
74
Price
$42.84
Market Cap
$3.32B
Part 1 · What the company is worth
Overview
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$562M
Trailing 12 months (through 6/30/2026)
Net Income
$114M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$127M
Total Equity
$1.31B
Total Liabilities
$96M
Current Ratio
9.16
Interest Coverage
-
Debt/EBITDA
0.51
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$43.39
Current Price
$42.84
Margin of Safety
+1.3%
Fair Value Range
$28.21 - $58.58
Estimation Methods
Valuation Metrics
P/E Ratio
29.62
ROE
5.1%
P/B Ratio
2.40
P/FCF
20.08
Gross Margin
71.7%
ROIC
5.9%
Profitability Radar
Value Creation (Economic Moat)
ROIC
5.9%
WACC
15.2%
ROIC − WACC
-9.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (20)
- EPS shows upward trend
- Price CAGR 18.52%
- ROIC 5.9%
- Gross Margin 71.7%
- P/FCF 20.08
- P/B Ratio 2.40
- Debt/Equity ratio
- Operating Margin 18.8%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 8.6%
- Revenue Growth 5Y 34.5%
- Analyst Consensus 84% Buy
- Earnings Surprise avg 93.2%
- Earnings Quality (OCF/NI) 1.56
- Net Margin Trend 20.4% vs 5.5%
- Piotroski F-Score 8/9
Failed (4)
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Share Dilution 3.9%
Unavailable (3)
- Dividend Payout NaN%
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Strong financial health
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Issuing new shares, diluting ownership
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Marc A. Stapley | CEO & Director | 55 |
| Ms. Rebecca Chambers | Executive VP & CFO | 47 |
| Dr. Phillip G. Febbo M.D. | Chief Scientific & Medical Officer | 59 |
| Ms. Annie McGuire | Executive VP, General Counsel & Head of Market Access | 44 |
| Dr. John Leite Ph.D. | Global Chief Commercial Officer | 53 |
| Dr. Keith Gligorich Ph.D. | Senior Vice President of Global Operations | - |
| Mr. Jonathan Wygant | VP & Chief Accounting Officer | 54 |
| Dr. Kevin Richard Haas Ph.D. | Chief Development and Technology Officer | 40 |
| Mr. Steven French | Senior VP & Chief Information Officer | - |
| Ms. Kelly Gura | Director of Investor Relations | - |
Audit Risk
2
Board Risk
2
Compensation Risk
5
Shareholder Rights Risk
4
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for VCYT, sourced from Markets Gazette.
- 2/25/2026NEUTRALVeracyte (VCYT) Q4 2025 Earnings Call Transcript
Investors are keenly awaiting the transcript of Veracyte Inc.'s (VCYT) Q4 2025 earnings call, scheduled for February 25, 2026. While the announcement of such an event is standard for publicly traded companies, the current unavailability of the actual transcript content prevents any in-depth analysis of the financial data, future outlook, or strategic decisions discussed. The eventual release of these details will be crucial for understanding the company's performance and projections, potentially influencing market sentiment and investment decisions. Without this information, the market remains in a holding pattern, awaiting further clarity.
via Markets Gazette